poisar

Stocks · News reference

Heron Therapeutics Q2 EPS $(0.03) Misses $(0.01) Estimate, Sales $37.666M Miss $42.200M Estimate

Benzinga Newsdesk

Heron Therapeutics (NASDAQ:HRTX) reported quarterly losses of $(0.03) per share which missed the analyst consensus estimate of $(0.01) by Infinity percent. This is a 50 percent decrease over losses of $(0.02) per share

More stocks newsConnected markets

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

HRTX
Source
benzinga
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  1. SEC EDGAR

    8-K filing — HERON THERAPEUTICS, INC. /DE/ (HRTX)

    Filed: 2026-08-14 AccNo: 0001193125-26-352403 Size: 231 KB Item 1.01: Entry into a Material Definitive Agreement Item 3.03: Material Modifications to Rights of Security Holders Item 9.01: Financial Statements and Exhibits

    HRTX